Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

On January 19, 2023, Leone Patterson notified Eliem Therapeutics, Inc. (Eliem, or the Company) of her decision to resign from the Board of Directors of the Company (the Board), effective immediately. In submitting her resignation, Ms. Leone did not express any disagreement on any matter relating to the Company's operations, policies or practices.

In connection with Ms. Patterson's resignation from the Board, the Board (i) decreased the authorized number of directors on the Board from seven to six and (ii) reconstituted the composition of its Audit Committee and Nominating and Corporate Governance Committee. The Audit Committee now consists of Adam Rosenberg (Chairperson), Simon Tate and Judith Dunn. The Nominating and Corporate Governance Committee now consists of Simon Tate (Chairperson) and Liam Ratcliffe. The Board has determined (i) that each member of the Audit Committee meets the independence, financial sophistication and other requirements for audit committee members set forth under applicable Nasdaq listing standards and Rule 10A-3 of Schedule 14A under the Securities Exchange Act of 1934, as amended (the Exchange Act), and (ii) that Mr. Rosenberg is an "audit committee financial expert" as defined in the rules and regulations under the Exchange Act.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses